

## WEB MATERIAL

### Active Postlicensure Safety Surveillance for Recombinant Zoster Vaccine Using Electronic Health Record Data




Jennifer C. Nelson, Ernesto Ulloa-Pérez, Onchee Yu, et al.




#### Contents

Web Figures 1 and 2

**Web Figure 1.** Forest plots of propensity-score–adjusted relative risks (RRs) of 6 primary outcomes from end-of-surveillance exploratory analyses comparing rates of adverse events between recombinant zoster vaccine (RZV) vaccinees and well-visit comparators in the Vaccine Safety Datalink study population, January 2018–December 2019. At site 3, where no Bell’s palsy or convulsion outcomes occurred in the RZV group, we provide the estimated RR as 0 with a 95% confidence interval (CI) of (0, 0), since the variance was not estimable. *Note:* The upper bound of the 95% CI for Bell’s palsy at site 5 is 19.2 (not shown).

[Graph appears on next page.]





Estimated Relative Risk (95% CI)

**Web Figure 2.** Forest plots of propensity-score–adjusted relative risks of 8 secondary outcomes from end-of-surveillance exploratory analyses comparing rates of adverse events between recombinant zoster vaccine vaccinees and well-visit comparators in a Vaccine Safety Datalink study population, January 2018–December 2019. *Note:* The upper bounds of the 95% confidence intervals (CIs) for local reaction at sites 2 and 7 were 9.83 and 18.57, respectively (not shown). ED, emergency department.

[Graph appears on next page.]

